62 results
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
6 Nov 19
Coherus BioSciences Reports Corporate Highlights and Third Quarter 2019 Financial Results
4:38pm
environment to the ophthalmology therapeutic commercial environment.
Coherus and Pfizer entered into a license and settlement agreement relating to Coherus … commercial environment to the ophthalmology therapeutic commercial environment; Coherus’ ability to advance the development of CHS-2020, a biosimilar
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
2 Aug 23
Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights
4:05pm
”), if completed. The merger is expected to significantly advance Coherus’ next-generation immuno-oncology pipeline focused on the tumor micro-environment
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
6 Nov 23
Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights
4:31pm
significantly advanced Coherus’ next-generation immuno-oncology pipeline focused on the tumor micro-environment with clinical stage anti-IL-27 and anti-CCR8
DRS
EX-10.9
nckwd0ymx63b14yzvo
4 Aug 14
Draft registration statement
12:00am
8-K
EX-1.1
2xsy tqvjodl8z85ctj
25 May 18
Coherus Announces Proposed Public Offering of Common Stock
4:01pm
8-K
EX-1.1
j4hkly7jjy x0
18 May 23
Other Events
5:02pm